secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2022-05-26T23:59:59+00:00
Accession:  0001558370-22-009406
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix announces five poster presentations at Fabry Disease conference
------------------------------------------------------------------------

- Posters cover pegunigalsidase alfa data from BALANCE, BRIDGE, BRIGHT, and extension studies.
- Conference is the 7th Update on Fabry Disease in Würzburg, Germany, May 29-31, 2022.
- Posters and abstracts will be posted on Protalix's website under Investors/Presentations.
- Data include 24-month renal function results from Phase III BALANCE study.
- No specific efficacy or safety numbers were disclosed in the press release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837022009406/0001558370-22-009406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837022009406/plx-20220526x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-009406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer